Patents by Inventor Andrew Sharp

Andrew Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8834473
    Abstract: Disclosed are lockable instrument assemblies for quick and easy configuration of surgical instrumentation. The assemblies are operable between a locked and unlocked position, and generally include an aperture having a shaped profile which receives an adjustment member therein. When the assemblies are placed in a locked assembly configuration, the adjustment member is prevented from rotating or translating within the aperture. When the assemblies are placed in an unlocked assembly configuration, the adjustment member is permitted to rotate or translate within the aperture. Also disclosed are methods of using and making lockable instrument assemblies.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: September 16, 2014
    Assignee: Smith & Nephew, Inc.
    Inventors: Roger Ryan Dees, Jr., Jeffrey Andrew Sharp
  • Patent number: 8785628
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 22, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Publication number: 20140186999
    Abstract: An apparatus for the wafer level packaging (WLP) of micro-bolometer vacuum package assemblies (VPAs), in one embodiment, includes a wafer alignment and bonding chamber, a bolometer wafer chuck and a lid wafer chuck disposed within the chamber in vertically facing opposition to each other, means for creating a first ultra-high vacuum (UHV) environment within the chamber, means for heating and cooling the bolometer wafer chuck and the lid wafer chuck independently of each other, means for moving the lid wafer chuck in the vertical direction and relative to the bolometer wafer chuck, means for moving the bolometer wafer chuck translationally in two orthogonal directions in a horizontal plane and rotationally about a vertical axis normal to the horizontal plane, and means for aligning a fiducial on a bolometer wafer held by the bolometer wafer chuck with a fiducial on a lid wafer held by the lid wafer chuck.
    Type: Application
    Filed: December 26, 2013
    Publication date: July 3, 2014
    Applicant: FLIR Systems, Inc.
    Inventors: Paul Schweikert, Andrew Sharpe, Gregory A. Carlson, Alex Matson, Scott Vilander, Bob Zahuta, Richard M. Goeden
  • Publication number: 20140163561
    Abstract: Instruments for use in anterior approach total hip arthroplasty. Instruments according to certain embodiments of the invention connect to a shaping member such as a broach, reamer or osteotome that is used to prepare the intramedullary canal of a desired femur or other bone for total hip arthroplasty. Such an instrument according to such embodiments can be configurable to allow operation on either the left or right leg, and in doing so to provide lateral offset and anterior offset of the instrument handle relative to the shaping member so that the patient's gut, musculature or other bodily portions may be avoided while still providing desired leverage and control over the shaping member to prepare the intramedullary canal.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: SMITH & NEPHEW, INC.
    Inventors: Jeffrey Andrew Sharp, Luke Andrew Gibson, David C. Kelman
  • Publication number: 20140088117
    Abstract: Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 25, 2013
    Publication date: March 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Jason Burch, Minghua Sun, Xiaojing Wang, Wesley Blackaby, Alastair James Hodges, Andrew Sharpe
  • Publication number: 20140080801
    Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Alastair James Hodges, Mizio Matteucci, Andrew Sharpe, Minghua Sun, Xiaojing Wang, Vickie H. Tsui
  • Patent number: 8653105
    Abstract: A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: February 18, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Patent number: 8637543
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Patent number: 8614206
    Abstract: Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: December 24, 2013
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Alastair James Hodges, Mizio Matteucci, Andrew Sharpe, Minghua Sun, Xiaojing Wang, Vickie H. Tsui
  • Patent number: 8513284
    Abstract: A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: August 20, 2013
    Assignee: UCB Pharma, S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Jonathan David MacDonald, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Patent number: 8399483
    Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions, said substituted derivatives having the general formula
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: March 19, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Rees Allen, George Martin Buckley, Roland Bürli, John Richard Davenport, Natasha Kinsella, Christopher James Lock, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Andrew James Ratcliffe, Marianna Dilani Richard, Verity Margaret Sabin, Andrew Sharpe, Laura Jane Tait, Graham John Warrellow, Sophie Caroline Williams
  • Publication number: 20130018057
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 17, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Roland Bürli, Alan Findlay Haughan, Mîzio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Publication number: 20130012517
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 10, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Patent number: 8324204
    Abstract: A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: December 4, 2012
    Assignee: UCB Pharma SA
    Inventors: Rikki Peter Alexander, Stuart Bailey, Stephen Brand, Daniel Christopher Brookings, Julien Alistair Brown, Alan Findlay Haughan, Natasha Kinsella, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Marianna Dilani Richard, Andrew Sharpe, Laura Jane Tait
  • Publication number: 20120277166
    Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
    Type: Application
    Filed: May 25, 2011
    Publication date: November 1, 2012
    Applicant: XENOME LIMITED
    Inventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
  • Publication number: 20120123422
    Abstract: Patient-matched surgical instruments, and methods for making patient-matched surgical instruments, may include patient-matched surgical instruments having an anatomy facing side with several discrete, physically separate anatomy contacting portions configured to match the anatomy of a particular patient. The anatomy contacting portions may be one or more of non-uniform in distribution, non-uniform in shape or non-uniform in surface area.
    Type: Application
    Filed: June 10, 2011
    Publication date: May 17, 2012
    Inventors: Aashiish Agnihotri, Patrick Brian Conway, David L. Evans, Luke Andrew Gibson, Jennifer Allyn Griffin, Michael Dean Hughes, David Timothy Mehl, Abraham Biglari Salehi, Jeffrey Andrew Sharp, Maroun Hanna Tarsha, Andrew Justin Wald, Thomas S. Wolfe
  • Publication number: 20120116562
    Abstract: Patient-matched surgical instruments, and methods for making patient-matched surgical instruments, may include patient-matched surgical instruments having an anatomy facing side with several discrete, physically separate anatomy contacting portions configured to match the anatomy of a particular patient. The anatomy contacting portions may be one or more of non-uniform in distribution, non-uniform in shape or non-uniform in surface area.
    Type: Application
    Filed: June 10, 2011
    Publication date: May 10, 2012
    Applicant: Smith & Nephew, Inc.
    Inventors: Aashiish Agnihotri, Patrick Brian Conway, David L. Evans, Luke Andrew Gibson, Jennifer Allyn Griffin, Michael Dean Hughes, David Timothy Mehl, Abraham Biglari Salehi, Jeffrey Andrew Sharp, Maroun Hanna Tarsha, Andrew Justin Wald, Thomas S. Wolfe
  • Publication number: 20120095005
    Abstract: A series of substituted pyrazolo[1,5-?][1,3,5]triazine and pyrazolo[1,5-?j-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).
    Type: Application
    Filed: May 19, 2010
    Publication date: April 19, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Barry John Langham, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Publication number: 20120077815
    Abstract: A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: February 11, 2010
    Publication date: March 29, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Publication number: 20120053167
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: March 2, 2010
    Publication date: March 1, 2012
    Applicant: UCB PHARMA, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe